Orchestra BioMed Holdings (OBIO) Accounts Payables (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has 7 years of Accounts Payables data on file, last reported at $6.3 million in Q1 2026.

• Quarterly Accounts Payables rose 13.48% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (up 13.48% YoY) and the FY2025 annual result came in at $6.1 million, up 18.72% from the prior year.
• Accounts Payables grew to $6.3 million in Q1 2026 per OBIO's latest filing, from $6.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $8.5 million in Q3 2025 and bottomed at $103607.0 in Q1 2022.
• The 5-year median for Accounts Payables is $4.0 million (2022), against an average of $4.0 million.
• The widest annual swing landed in 2022, when Accounts Payables jumped 16912.75%; it then fell 26.92% in 2023.
• Tracing OBIO's Accounts Payables over 5 years: stood at $4.0 million in 2022, then slipped by 26.92% to $2.9 million in 2023, then surged by 77.03% to $5.1 million in 2024, then increased by 18.72% to $6.1 million in 2025, then rose by 3.58% to $6.3 million in 2026.
• Per Business Quant, the three latest OBIO Accounts Payables figures stand at $6.3 million (Q1 2026), $6.1 million (Q4 2025), and $8.5 million (Q3 2025).

Peer Comparison